GlassScriptPhysician profile
Cheryl E Kyinn
NPI 1649570284
$102,595.04
in general payments reported to CMS, 2019-2025
35 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,480 · 2022: $8,141 · 2023: $14K · 2024: $32K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $21K · Consulting Fee: $15K · Travel and Lodging: $10K · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,072.14 |
| Food and Beverage | $21,374.05 |
| Consulting Fee | $14,808.86 |
| Travel and Lodging | $10,466.38 |
| Education | $252.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $50,421.96 | 2021-2025 | Nuplazid |
| Abbvie INC. | $24,869.88 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $8,344.07 | 2021-2025 | Rytary, Crexont |
| Teva Pharmaceuticals USA, INC. | $2,874.97 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $2,284.01 | 2022-2025 | Myobloc, Gocovri, Qelbree |
| Boston Scientific Corporation | $1,444.67 | 2023-2025 | General - Dbs, Vercise |
| Tanabe Pharma America, INC. | $1,319.80 | 2025 | |
| Neurocrine Biosciences, INC. | $1,318.98 | 2021-2025 | Ingrezza |
| Adamas Pharmaceuticals, INC. | $1,236.15 | 2021 | |
| Medtronic, INC. | $997.35 | 2022-2025 | Percept PC Brainsense, Activa PC |
| Merz Pharmaceuticals, LLC | $958.34 | 2021-2025 | Xeomin, Inbrija |
| Kyowa Kirin, INC. | $915.10 | 2021-2025 | Nourianz |
| Pfizer INC. | $707.48 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $523.85 | 2021-2025 | Dysport |
| Global Kinetics USA Corporation | $500.00 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $451.06 | 2021-2025 | Emgality, Amyvid, Reyvow |
| Biohaven Pharmaceuticals, INC. | $424.08 | 2021 | |
| Acorda Therapeutics, INC | $356.16 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $343.88 | 2025 | Lumryz |
| Abbott Laboratories | $284.49 | 2021-2023 | Infinity |
| Avion Pharmaceuticals | $250.81 | 2022-2023 | Dhivy |
| Supernus Pharmaceuticals, INC. | $242.46 | 2022-2025 | |
| Impel Pharmaceuticals INC. | $212.64 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $209.49 | 2022 | |
| Eisai INC. | $208.21 | 2021-2025 | |
| Insightec,INC | $159.37 | 2022 | |
| Allergan, INC. | $152.08 | 2021-2022 | |
| Ucb, INC. | $133.21 | 2021-2022 | |
| Amgen INC. | $123.07 | 2021-2022 | |
| Axsome Therapeutics, INC. | $106.91 | 2025 | Symbravo |
| Biogen, INC. | $89.43 | 2021 | |
| Hologic Sales and Service, LLC | $51.12 | 2023 | Novasure |
| Impel Pharmaceuticals LLC | $43.01 | 2025 | Trudhesa |
| Cala Health, INC. | $22.86 | 2023 | Cala Kiq, Cala Trio |
| Lundbeck LLC | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Kyinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.